Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen December 29, 2022 AutoBot News 0 The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”